Back to Peptides
CognitiveMedium Risk

VIP

Also known as: Vasoactive Intestinal Peptide, Vasoactive Intestinal Polypeptide

Half-life:
~1-2 minutes (plasma)

Administration Routes

intranasalintravenous
PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Mechanism of Action

Pleiotropic neuropeptide binding VPAC1/VPAC2 receptors; suppresses neuroinflammation, regulates circadian rhythm via SCN, modulates immune response

A 28-amino acid neuropeptide with potent anti-inflammatory and neuroprotective effects. Commonly used in Chronic Inflammatory Response Syndrome (CIRS) protocols.

Primary Research Areas

  • neuroprotection
  • anti-inflammatory (CNS)
  • CIRS treatment
  • circadian rhythm regulation

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Consult a healthcare professional before use.

Regulatory Status

Research OnlyNot Evaluated by FDA

Endogenous 28-aa neuropeptide. No FDA-approved product. Inhaled VIP studied in Phase 2 for pulmonary arterial hypertension (Santhera); program not advanced. No NDA filed. Research use only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Where to Find VIP